Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors
MA Nauck, JJ Meier, MA Cavender, M Abd El Aziz… - Circulation, 2017 - Am Heart Assoc
Potentiation of glucagon-like peptide-1 (GLP-1) action through selective GLP-1 receptor
(GLP-1R) agonism or by prevention of enzymatic degradation by inhibition of dipeptidyl …
(GLP-1R) agonism or by prevention of enzymatic degradation by inhibition of dipeptidyl …
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
SR Salpeter, E Greyber, GA Pasternak… - … of systematic reviews, 2010 - cochranelibrary.com
Background Metformin is an oral anti‐hyperglycemic agent that has been shown to reduce
total mortality compared to other anti‐hyperglycemic agents, in the treatment of type 2 …
total mortality compared to other anti‐hyperglycemic agents, in the treatment of type 2 …
Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline update from the American College of Physicians
A Qaseem, MJ Barry, LL Humphrey… - Annals of internal …, 2017 - acpjournals.org
Description: The American College of Physicians (ACP) developed this guideline to present
the evidence and provide clinical recommendations on oral pharmacologic treatment of type …
the evidence and provide clinical recommendations on oral pharmacologic treatment of type …
Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3)
G Umpierrez, S Tofé Povedano, F Pérez Manghi… - Diabetes …, 2014 - Am Diabetes Assoc
OBJECTIVE Compare the efficacy and safety of monotherapy with dulaglutide, a once-
weekly GLP-1 receptor agonist, to metformin-treated patients with type 2 diabetes. The …
weekly GLP-1 receptor agonist, to metformin-treated patients with type 2 diabetes. The …
Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis
Objective To assess the efficacy and safety of dipeptidyl peptidase-4 (DPP-4) inhibitors
compared with metformin as monotherapy, or with other commonly used hypoglycaemic …
compared with metformin as monotherapy, or with other commonly used hypoglycaemic …
Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis
Aims/hypothesis The aim of this work was to compare the glucose-lowering efficacy of
dipeptidyl peptidase-4 (DPP-4) inhibitors between Asian and non-Asian patients with type 2 …
dipeptidyl peptidase-4 (DPP-4) inhibitors between Asian and non-Asian patients with type 2 …
Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus …
J Rosenstock, L Hansen, P Zee, Y Li, W Cook… - Diabetes …, 2015 - Am Diabetes Assoc
OBJECTIVE This study compared the efficacy and safety of dual add-on of saxagliptin plus
dapagliflozin versus saxagliptin and dapagliflozin added on alone in patients with type 2 …
dapagliflozin versus saxagliptin and dapagliflozin added on alone in patients with type 2 …
Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies
L Li, S Li, K Deng, J Liu, PO Vandvik, P Zhao, L Zhang… - bmj, 2016 - bmj.com
Objectives To examine the association between dipeptidyl peptidase-4 (DPP-4) inhibitors
and the risk of heart failure or hospital admission for heart failure in patients with type 2 …
and the risk of heart failure or hospital admission for heart failure in patients with type 2 …
Assessment of pancreatic β-cell function: review of methods and clinical applications
E Cersosimo, C Solis-Herrera… - Current diabetes …, 2014 - ingentaconnect.com
Type 2 diabetes mellitus (T2DM) is characterized by a progressive failure of pancreatic β-
cell function (BCF) with insulin resistance. Once insulin over-secretion can no longer …
cell function (BCF) with insulin resistance. Once insulin over-secretion can no longer …
Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial
RR Henry, AV Murray, MH Marmolejo… - … journal of clinical …, 2012 - Wiley Online Library
Background: Combining metformin (XR) with dapagliflozin to initiate pharmacotherapy in
patients with type 2 diabetes (T2D) and high baseline HbA1c may be advantageous. We …
patients with type 2 diabetes (T2D) and high baseline HbA1c may be advantageous. We …